New York, New York–(Newsfile Corp. – January 12, 2025) – WHY: New York, NY, January 11, 2025. The Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: LON: ) between February 23, 2022 and December 17, 2024, both dates inclusive (” Class period”), z Lead plaintiff deadline February 21, 2025 in a securities class-action lawsuit filed for the first time by the firm.
SO WHAT: If you purchased AstraZeneca (NASDAQ: ) securities during the Class Period, you may be entitled to compensation without paying any out-of-pocket fees or expenses through an extraordinary fee arrangement.
WHAT TO DO NEXT: To join the AstraZeneca class action, go to https://rosenlegal.com/submit-form/?case_id=1331 or call Phillip Kim, Esq. For class action information, call toll-free at 866-767-3653 or email case@rosenlegal.com. A class action lawsuit has already been filed. If you want to serve as a lead prosecutor, you must go to court no later than 21.2.2025. The lead plaintiff is the representative party acting on behalf of the other class members in the litigation.
WHY ROSEN'S LAW: We encourage investors to select a qualified advisor with a track record of success in leadership roles. Notifying firms often do not have comparable experience, resources, or any meaningful mutual recognition. Many of these firms do not actually litigate securities class actions, but are merely intermediaries who refer clients or partners to the law firms that actually litigate. Be wise in choosing an advisor. The Rosen Law Firm represents investors worldwide and focuses its practice on securities class actions and shareholder derivative litigation. The Rosen law firm achieved the largest securities class action settlement against a Chinese company at the time. Rosen Law Firm ranked #1 by ISS Securities Class Action (WA:) Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the firm secured more than $438 million for investors. In 2020, founding partner Laurence Rosen was named a Law 360 Titan of Litigation. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
CASE DETAILS: According to the lawsuit, the defendants made materially false and/or misleading statements and/or failed to disclose during the Class Period that: (1) AstraZeneca engaged in insurance fraud in China; (2) as a result, AstraZeneca faced increased legal exposure in China, which ultimately resulted in the Chinese president of AstraZeneca being detained by Chinese law enforcement authorities; (3) as a result, AstraZeneca underestimated its legal risks; (4) the foregoing, if disclosed, could materially harm AstraZeneca's business activities in China; and (5) as a result, Defendants' representations about its business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details came to market, the lawsuit claims, investors suffered damages.
To join the AstraZeneca class action, go to https://rosenlegal.com/submit-form/?case_id=1331 call Phillip Kim, Esq. For class action information, call toll-free at 866-767-3653 or email case@rosenlegal.com.
No class has been certified. Until the class is certified, you are not represented by an attorney unless you retain one. You can choose an advisor of your choice. You can also remain an absent member of the class and do nothing at this time. An investor's ability to participate in any future recovery does not depend on whether it is the lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https:/ /www.facebook.com/rosenlawfirm.
Attorney Advertising. Previous results do not guarantee a similar result.
——————————
Contact details:
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236846
